Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139


Coordination polymers of CdII and PbII with croconate show remarkable differences in coordination patterns: a structural and spectroscopic study.

Silverman JA, Mathivathanan L, Govor EV, Raptis RG, Kavallieratos K.

Acta Crystallogr C Struct Chem. 2019 Jul 1;75(Pt 7):935-940. doi: 10.1107/S2053229619007277. Epub 2019 Jun 14.


Perspective on Antibacterial Lead Identification Challenges and the Role of Hypothesis-Driven Strategies.

McDowell LL, Quinn CL, Leeds JA, Silverman JA, Silver LL.

SLAS Discov. 2019 Apr;24(4):440-456. doi: 10.1177/2472555218818786.


Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study.

Shah MA, Starodub A, Sharma S, Berlin J, Patel M, Wainberg ZA, Chaves J, Gordon M, Windsor K, Brachmann CB, Huang X, Vosganian G, Maltzman JD, Smith V, Silverman JA, Lenz HJ, Bendell JC.

Clin Cancer Res. 2018 Aug 15;24(16):3829-3837. doi: 10.1158/1078-0432.CCR-17-2469. Epub 2018 Apr 24.


The Drug-Drug Interaction Profile of Presatovir.

Xin Y, Weng W, Murray BP, Eisenberg EJ, Chien JW, Ling J, Silverman JA.

J Clin Pharmacol. 2018 Jun;58(6):771-780. doi: 10.1002/jcph.1073. Epub 2018 Feb 7.


Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical Development.

Zheng J, Xin Y, Zhang J, Subramanian R, Murray BP, Whitney JA, Warr MR, Ling J, Moorehead L, Kwan E, Hemenway J, Smith BJ, Silverman JA.

Drug Metab Dispos. 2018 Mar;46(3):237-247. doi: 10.1124/dmd.117.078899. Epub 2018 Jan 8.


Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.

Xin Y, Kawashima J, Weng W, Kwan E, Tarnowski T, Silverman JA.

J Clin Pharmacol. 2018 Apr;58(4):522-532. doi: 10.1002/jcph.1050. Epub 2017 Dec 28.


Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Early Results.

Yassaie O, Silverman JA, Gilling PJ.

Curr Urol Rep. 2017 Oct 18;18(12):91. doi: 10.1007/s11934-017-0743-2. Review.


The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects.

Xin Y, Shao L, Maltzman J, Stefanidis D, Hemenway J, Tarnowski T, Deng W, Silverman JA.

Clin Pharmacol Drug Dev. 2018 Mar;7(3):277-286. doi: 10.1002/cpdd.397. Epub 2017 Oct 11.


Tuberculosis, a rare cause of haematuria.

Silverman JA, Patel K, Hotston M.

BMJ Case Rep. 2016 Jul 20;2016. pii: bcr2016216428. doi: 10.1136/bcr-2016-216428.


Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.

Sandborn WJ, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG.

Aliment Pharmacol Ther. 2016 Jul;44(2):157-69. doi: 10.1111/apt.13653. Epub 2016 May 24.


The effects of malnutrition on cardiac function in African children.

Silverman JA, Chimalizeni Y, Hawes SE, Wolf ER, Batra M, Khofi H, Molyneux EM.

Arch Dis Child. 2016 Feb;101(2):166-71. doi: 10.1136/archdischild-2015-309188. Epub 2015 Nov 9.


Mapping of amino acid substitutions conferring herbicide resistance in wheat glutathione transferase.

Govindarajan S, Mannervik B, Silverman JA, Wright K, Regitsky D, Hegazy U, Purcell TJ, Welch M, Minshull J, Gustafsson C.

ACS Synth Biol. 2015 Mar 20;4(3):221-7. doi: 10.1021/sb500242x. Epub 2014 Jun 13.


Case 1: Recurrent abdominal pain in an adolescent girl.

Silverman JA, Yeung AK, Jain S, Kavadas FD.

Paediatr Child Health. 2014 May;19(5):233-4. No abstract available.


Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium.

Mascio CT, Chesnel L, Thorne G, Silverman JA.

Antimicrob Agents Chemother. 2014 Jul;58(7):3976-82. doi: 10.1128/AAC.00124-14. Epub 2014 May 5.


Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy.

Kaplan LD, Deitcher SR, Silverman JA, Morgan G.

Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):37-42. doi: 10.1016/j.clml.2013.09.009. Epub 2013 Oct 1.


Increase in pediatric magnet-related foreign bodies requiring emergency care.

Silverman JA, Brown JC, Willis MM, Ebel BE.

Ann Emerg Med. 2013 Dec;62(6):604-608.e1. doi: 10.1016/j.annemergmed.2013.06.019. Epub 2013 Aug 6.


Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.

Silverman JA, Reynolds L, Deitcher SR.

J Clin Pharmacol. 2013 Nov;53(11):1139-45. doi: 10.1002/jcph.155. Epub 2013 Aug 17.


From physiology to pharmacy: developments in the pathogenesis and treatment of recurrent urinary tract infections.

Silverman JA, Schreiber HL 4th, Hooton TM, Hultgren SJ.

Curr Urol Rep. 2013 Oct;14(5):448-56. doi: 10.1007/s11934-013-0354-5. Review.


Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.

Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F.

Br J Haematol. 2013 Sep;162(5):631-8. doi: 10.1111/bjh.12446. Epub 2013 Jun 27.


Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies.

Song Y, Rubio A, Jayaswal RK, Silverman JA, Wilkinson BJ.

PLoS One. 2013;8(3):e58469. doi: 10.1371/journal.pone.0058469. Epub 2013 Mar 15.


Microbiology of urinary tract infections in Gaborone, Botswana.

Renuart AJ, Goldfarb DM, Mokomane M, Tawanana EO, Narasimhamurthy M, Steenhoff AP, Silverman JA.

PLoS One. 2013;8(3):e57776. doi: 10.1371/journal.pone.0057776. Epub 2013 Mar 4.


Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.

Silverman JA, Deitcher SR.

Cancer Chemother Pharmacol. 2013 Mar;71(3):555-64. doi: 10.1007/s00280-012-2042-4. Epub 2012 Dec 5. Review.


High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.

O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H.

J Clin Oncol. 2013 Feb 20;31(6):676-83. doi: 10.1200/JCO.2012.46.2309. Epub 2012 Nov 19.


Reduced pulmonary surfactant interaction of daptomycin analogs via tryptophan replacement with alternative amino acids.

He Y, Li J, Yin N, Herradura PS, Martel L, Zhang Y, Pearson AL, Kulkarni V, Mascio C, Howland K, Silverman JA, Keith DD, Metcalf CA.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6248-51. doi: 10.1016/j.bmcl.2012.08.013. Epub 2012 Aug 9.


In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.

Mascio CT, Mortin LI, Howland KT, Van Praagh AD, Zhang S, Arya A, Chuong CL, Kang C, Li T, Silverman JA.

Antimicrob Agents Chemother. 2012 Oct;56(10):5023-30. doi: 10.1128/AAC.00057-12. Epub 2012 Jul 16.


Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins.

Pogliano J, Pogliano N, Silverman JA.

J Bacteriol. 2012 Sep;194(17):4494-504. doi: 10.1128/JB.00011-12. Epub 2012 Jun 1.


Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

Zhong M, Gadek TR, Bui M, Shen W, Burnier J, Barr KJ, Hanan EJ, Oslob JD, Yu CH, Zhu J, Arkin MR, Evanchik MJ, Flanagan WM, Hoch U, Hyde J, Prabhu S, Silverman JA, Wright J.

ACS Med Chem Lett. 2012 Jan 31;3(3):203-6. doi: 10.1021/ml2002482. eCollection 2012 Mar 8.


LC-MS/MS characterization of phospholipid content in daptomycin-susceptible and -resistant isolates of Staphylococcus aureus with mutations in mprF.

Rubio A, Moore J, Varoglu M, Conrad M, Chu M, Shaw W, Silverman JA.

Mol Membr Biol. 2012 Feb;29(1):1-8. doi: 10.3109/09687688.2011.640948. Epub 2012 Jan 26.


VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus.

Mehta S, Cuirolo AX, Plata KB, Riosa S, Silverman JA, Rubio A, Rosato RR, Rosato AE.

Antimicrob Agents Chemother. 2012 Jan;56(1):92-102. doi: 10.1128/AAC.00432-10. Epub 2011 Oct 10.


Evaluating the activity of the RNA polymerase inhibitor myxopyronin B against Staphylococcus aureus.

Moy TI, Daniel A, Hardy C, Jackson A, Rehrauer O, Hwang YS, Zou D, Nguyen K, Silverman JA, Li Q, Murphy C.

FEMS Microbiol Lett. 2011 Jun;319(2):176-9. doi: 10.1111/j.1574-6968.2011.02282.x. Epub 2011 Apr 20.


Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists.

Zhong M, Hanan EJ, Shen W, Bui M, Arkin MR, Barr KJ, Evanchik MJ, Hoch U, Hyde J, Martell JR, Oslob JD, Paulvannan K, Prabhu S, Silverman JA, Wright J, Yu CH, Zhu J, Flanagan WM.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):307-10. doi: 10.1016/j.bmcl.2010.11.014. Epub 2010 Nov 5.


Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.

Bedikian AY, Silverman JA, Papadopoulos NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies M, Hwu P.

J Clin Pharmacol. 2011 Aug;51(8):1205-12. doi: 10.1177/0091270010381499. Epub 2010 Oct 26.


Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus.

Rubio A, Conrad M, Haselbeck RJ, G C K, Brown-Driver V, Finn J, Silverman JA.

Antimicrob Agents Chemother. 2011 Jan;55(1):364-7. doi: 10.1128/AAC.00429-10. Epub 2010 Oct 25.


Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.

Zhong M, Shen W, Barr KJ, Arbitrario JP, Arkin MR, Bui M, Chen T, Cunningham BC, Evanchik MJ, Hanan EJ, Hoch U, Huen K, Hyde J, Kumer JL, Lac T, Lawrence CE, Martell JR, Oslob JD, Paulvannan K, Prabhu S, Silverman JA, Wright J, Yu CH, Zhu J, Flanagan WM.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5269-73. doi: 10.1016/j.bmcl.2010.06.145. Epub 2010 Jul 23.


Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.

Advani RH, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, Hoch U, Silverman JA, Havrilla NA, Berman CJ, Fox JA, Allen RS, Adelman DC.

Clin Cancer Res. 2010 Apr 1;16(7):2167-75. doi: 10.1158/1078-0432.CCR-09-2236. Epub 2010 Mar 16.


Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.

Nguyen KT, He X, Alexander DC, Li C, Gu JQ, Mascio C, Van Praagh A, Mortin L, Chu M, Silverman JA, Brian P, Baltz RH.

Antimicrob Agents Chemother. 2010 Apr;54(4):1404-13. doi: 10.1128/AAC.01307-09. Epub 2010 Jan 19.


Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.

Scatena CD, Kumer JL, Arbitrario JP, Howlett AR, Hawtin RE, Fox JA, Silverman JA.

Cancer Chemother Pharmacol. 2010 Oct;66(5):881-8. doi: 10.1007/s00280-009-1234-z. Epub 2010 Jan 8.


SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.

Arbitrario JP, Belmont BJ, Evanchik MJ, Flanagan WM, Fucini RV, Hansen SK, Harris SO, Hashash A, Hoch U, Hogan JN, Howlett AR, Jacobs JW, Lam JW, Ritchie SC, Romanowski MJ, Silverman JA, Stockett DE, Teague JN, Zimmerman KM, Taverna P.

Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. doi: 10.1007/s00280-009-1076-8. Epub 2009 Aug 1.


2-Aminobenzimidazoles as potent Aurora kinase inhibitors.

Zhong M, Bui M, Shen W, Baskaran S, Allen DA, Elling RA, Flanagan WM, Fung AD, Hanan EJ, Harris SO, Heumann SA, Hoch U, Ivy SN, Jacobs JW, Lam S, Lee H, McDowell RS, Oslob JD, Purkey HE, Romanowski MJ, Silverman JA, Tangonan BT, Taverna P, Yang W, Yoburn JC, Yu CH, Zimmerman KM, O'Brien T, Lew W.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5158-61. doi: 10.1016/j.bmcl.2009.07.016. Epub 2009 Jul 9.


Water-soluble prodrugs of an Aurora kinase inhibitor.

Oslob JD, Heumann SA, Yu CH, Allen DA, Baskaran S, Bui M, Delarosa E, Fung AD, Hashash A, Hau J, Ivy S, Jacobs JW, Lew W, Maung J, McDowell RS, Ritchie S, Romanowski MJ, Silverman JA, Yang W, Zhong M, Fuchs-Knotts T.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1409-12. doi: 10.1016/j.bmcl.2009.01.043. Epub 2009 Jan 19.


Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent.

Evanchik MJ, Allen D, Yoburn JC, Silverman JA, Hoch U.

Drug Metab Dispos. 2009 Mar;37(3):594-601. doi: 10.1124/dmd.108.023432. Epub 2008 Dec 12.


Hemoglobin köln and pregnancy.

Cheung VYT, Silverman JA.

J Obstet Gynaecol Can. 2008 Oct;30(10):907-909. doi: 10.1016/S1701-2163(16)32971-1.


Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.

Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.

Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65. doi: 10.1007/s00280-008-0850-3. Epub 2008 Oct 19.


A molecular ruler for measuring quantitative distance distributions.

Mathew-Fenn RS, Das R, Silverman JA, Walker PA, Harbury PA.

PLoS One. 2008;3(10):e3229. doi: 10.1371/journal.pone.0003229. Epub 2008 Oct 17.


Discovery of a potent and selective aurora kinase inhibitor.

Oslob JD, Romanowski MJ, Allen DA, Baskaran S, Bui M, Elling RA, Flanagan WM, Fung AD, Hanan EJ, Harris S, Heumann SA, Hoch U, Jacobs JW, Lam J, Lawrence CE, McDowell RS, Nannini MA, Shen W, Silverman JA, Sopko MM, Tangonan BT, Teague J, Yoburn JC, Yu CH, Zhong M, Zimmerman KM, O'Brien T, Lew W.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4880-4. doi: 10.1016/j.bmcl.2008.07.073. Epub 2008 Jul 24.


Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.

Cotroneo N, Harris R, Perlmutter N, Beveridge T, Silverman JA.

Antimicrob Agents Chemother. 2008 Jun;52(6):2223-5. doi: 10.1128/AAC.01410-07. Epub 2008 Mar 31.


Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization.

Muthaiyan A, Silverman JA, Jayaswal RK, Wilkinson BJ.

Antimicrob Agents Chemother. 2008 Mar;52(3):980-90. Epub 2007 Dec 17.


Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.

Mascio CT, Alder JD, Silverman JA.

Antimicrob Agents Chemother. 2007 Dec;51(12):4255-60. Epub 2007 Oct 8.


Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium.

Rand KH, Houck HJ, Silverman JA.

J Antimicrob Chemother. 2007 May;59(5):1017-20. Epub 2007 Mar 16.


Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus.

Friedman L, Alder JD, Silverman JA.

Antimicrob Agents Chemother. 2006 Jun;50(6):2137-45.

Supplemental Content

Loading ...
Support Center